Autologous dendritic cell vaccine (Dana-Farber Cancer Institute)

This autologous dendritic cell (DC) therapy platform was developed at the Dana-Farber Cancer Institute for the treatment of advanced melanoma. The platform encompasses two primary vaccine strategies investigated in Phase II clinical trials (e.g., NCT00064740): one involving DCs pulsed with the gp100 melanoma-associated peptide, and another involving DCs fused with the patient's own inactivated tumor cells (DC-tumor fusion). The fusion approach creates a hybrid cell that combines the potent antigen-presenting and costimulatory capabilities of dendritic cells with the full antigenic repertoire of the autologous tumor, aiming to induce a broad, polyclonal T-cell response. These vaccines are designed to stimulate the patient's immune system to recognize and eliminate melanoma cells in patients with stage III or IV disease.

Other names

autologous dendritic cells-Dana-Farber Cancer Institute-melanomaDC-tumor fusion vaccinegp100-pulsed dendritic cell vaccinegp-100-pulsed dendritic cell vaccinegp 100-pulsed dendritic cell vaccineautologous dendritic cell-tumor fusion vaccinetherapeutic autologous dendritic cells